PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2116 Views
-
Last post by NHE
-
- 0 Replies
- 994 Views
-
Last post by NHE
-
- 0 Replies
- 10186 Views
-
Last post by NHE
-
- 0 Replies
- 2023 Views
-
Last post by Firidion
-
- 1 Replies
- 1351 Views
-
Last post by vesta
-
- 0 Replies
- 2036 Views
-
Last post by frodo
-
- 0 Replies
- 1952 Views
-
Last post by NHE
-
- 0 Replies
- 1496 Views
-
Last post by NHE
-
- 4 Replies
- 2464 Views
-
Last post by JohnC777